Fibrosis in ulcerative colitis: Mechanisms, features, and consequences of a neglected problem

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 2198-2206

  Gordon, Ilyssa O ^a   Agrawal, Neha ^a   Goldblum, John R ^a   Fiocchi, Claudio ^a   Rieder, Florian ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Disease course; Inflammatory bowel disease; Stenosis; Stricture

Indexed keywords

ARTICLE; CLINICAL FEATURE; COLON CANCER; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INTESTINAL DYSMOTILITY; INTESTINAL FIBROSIS; INTESTINE STENOSIS; MOLECULAR PATHOLOGY; MORPHOLOGY; NEGLECTED DISEASE; NONHUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; COMPLICATION; FIBROSIS; PATHOLOGY; PROGNOSIS;

COLITIS, ULCERATIVE; FIBROSIS; HUMANS; PROGNOSIS;

EID: 84925610045     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000080     Document Type: Article

References (104)

1. Rieder F, Zimmermann EM, Remzi FH, et al. Crohn's disease complicated by strictures: a systematic review. Gut. 2013;62:1072-1084.
2. Friedman SL, Sheppard D, Duffield JS, et al. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013;5:167sr161.
3. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028-1040.
4. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-235.
5. Rieder F, Brenmoehl J, Leeb S, et al. Wound healing and fibrosis in intestinal disease. Gut. 2007;56:130-139.
6. Rieder F, Fiocchi C. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6:228-235.
7. Scales BS, Huffnagle GB. The microbiome in wound repair and tissue fibrosis. J Pathol. 2013;229:323-331.
8. Sponheim J, Pollheimer J, Olsen T, et al. Inflammatory bowel diseaseassociated interleukin-33 is preferentially expressed in ulcerationassociated myofibroblasts. Am J Pathol. 2010;177:2804-2815.
9. Fonseca-Camarillo G, Mendivil-Rangel E, Furuzawa-Carballeda J, et al. Interleukin 17 gene and protein expression are increased in patients with ulcerative colitis. Inflamm Bowel Dis. 2011;17:E135-E136.
10. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-564.
11. Grip O, Malm J, Veress B, et al. Increased presence of cells containing transforming growth factor alpha (TGF-alpha) in ulcerative colitis, both during active inflammation and in remission. Eur J Gastroenterol Hepatol. 2000;12:761-766.
12. Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7:16-26.
13. Kumagai S, Ohtani H, Nagai T, et al. Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med. 2001;195:21-33.
14. Yamagata M, Mikami T, Tsuruta T, et al. Submucosal fibrosis and basicfibroblast growth factor-positive neutrophils correlate with colonic stenosis in cases of ulcerative colitis. Digestion. 2011;84:12-21.
15. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease- current knowledge and future perspectives. J Crohns Colitis. 2008;2: 279-290.
16. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol. 1998;152:1005-1014.
17. Matsuno K, Adachi Y, Yamamoto H, et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol. 2003;38:348-354.
18. Liu X, Xiao SY, Plesec TP, et al. Collagenous colitis in children and adolescents: study of 7 cases and literature review. Mod Pathol. 2013;26: 881-887.
19. Rieder F, Georgieva M, Schirbel A, et al. Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflamm Bowel Dis. 2010;16:1505-1513.
20. Leeb SN, Vogl D, Grossmann J, et al. Autocrine fibronectin-induced migration of human colonic fibroblasts. Am J Gastroenterol. 2004;99: 335-340.
21. Leeb SN, Vogl D, Gunckel M, et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology. 2003;125:1341-1354.
22. Brittan M, Chance V, Elia G, et al. A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts. Gastroenterology. 2005;128:1984-1995.
23. Sazuka S, Katsuno T, Nakagawa T, et al. Fibrocytes are involved in inflammation as well as fibrosis in the pathogenesis of Crohn's disease. Dig Dis Sci. 2013.
24. Lawrance IC, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:226-236.
25. Leite AZ, De La Motte C, Strong SA, et al. Isolation and functional characterization of human intestinal mucosal stellate cells (Abstract). Gastroenterology. 2002;122:A111.
26. Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelialto-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol. 2012;179:2660-2673.
27. Flier SN, Tanjore H, Kokkotou EG, et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem. 2010;285:20202-20212.
28. Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology. 2003;124: 1866-1878.
29. Rieder F, Bhilocha S, Schirbel A, et al. Activation of toll-like receptor (TLR) 5 induces a pro-fibrogenic phenotype on human intestinal myofibroblasts (HIF)-a novel pathway mediated by Caspase 1 (Abstract). Gastroenterology. 2011;142:S116.
30. Rieder F, Kessler S, Sans M, et al. Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol. 2012;303:G786-G801.
31. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
32. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2011;10:826-837.
33. Dardenne AD, Wulff BC, Wilgus TA. The alarmin HMGB-1 influences healing outcomes in fetal skin wounds. Wound Repair Regen. 2013;21: 282-291.
34. van Nieuwenhoven FA, Hemmings KE, Porter KE, et al. Combined effects of interleukin-1alpha and transforming growth factor-beta1 on modulation of human cardiac fibroblast function. Matrix Biol. 2013;32:399-406.
35. Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology. 2008;47:1394-1400.
36. Johnson LA, Luke A, Sauder K, et al. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a "Top-Down" approach to intestinal fibrosis in mice. Inflamm Bowel Dis. 2012;18:460-471.
37. Nakamura T, Iwanaga K, Murata T, et al. ATP induces contraction mediated by the P2Y(2) receptor in rat intestinal subepithelial myofibroblasts. Eur J Pharmacol. 2011;657:152-158.
38. Burke JP, Cunningham MF, Watson RW, et al. Bacterial lipopolysaccharide promotes profibrotic activation of intestinal fibroblasts. Br J Surg. 2010;97:1126-1134.
39. Burke JP, Watson RW, Mulsow JJ, et al. Endoglin negatively regulates transforming growth factor beta1-induced profibrotic responses in intestinal fibroblasts. Br J Surg. 2010;97:892-901.
40. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782.
41. Goldberg HI, Caruthers SB Jr, Nelson JA, et al. Radiographic findings of the national Cooperative Crohn's disease study. Gastroenterology. 1979; 77:925-937.
42. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33:938-941.
43. De Dombal FT, Watts JM, Watkinson G, et al. Local complications of ulcerative colitis: stricture, pseudopolyposis, and carcinoma of colon and rectum. Br Med J. 1966;1:1442-1447.
44. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. III. complications. Gut. 1964;5:1-22.
45. Lashner BA, Turner BC, Bostwick DG, et al. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci. 1990;35: 349-352.
46. Warren S, Sommers SC. Pathogenesis of ulcerative colitis. Am J Pathol. 1949;25:657-679.
47. Marshak RH, Bloch C, Wolf BS. The Roentgen findings in strictures of the Colon associated with ulcerative and Granulomatous colitis. Am J Roentgenol Radium Ther Nucl Med. 1963;90:709-716.
48. Hunt RH, Teague RH, Swarbrick ET, et al. Colonoscopy in management of colonic strictures. Br Med J. 1975;3:360-361.
49. Van Moerkercke W, Deboever G, Lambrecht G, et al. Severe bridging fibrosis of the colon in a man with inflammatory bowel disease. Endoscopy. 2007;39(suppl 1):E294.
50. Kirsner JB, Palmer WL, Klotz A. Reversibility in ulcerative colitis; clinical and roentgenologic observations. Radiology. 1951;57:1-14.
51. Goulston SJ, McGovern VJ. The nature of benign strictures in ulcerative colitis. N Engl J Med. 1969;281:290-295.
52. Edling NP, Eklof O. Radiologic findings and prognosis in ulcerative colitis. Acta Chir Scand. 1961;121:299-308.
53. Lennard-Jones JE, Lockhart-Mummery HE, Morson BC. Clinical and pathological differentiation of Crohn's disease and proctocolitis. Gastroenterology. 1968;54:1162-1170.
54. Lumb G. Pathology of ulcerative colitis. Gastroenterology. 1961;40: 290-298.
55. Sparberg M, Fennessy J, Kirsner JB. Ulcerative proctitis and mild ulcerative colitis: a study of 220 patients. Medicine. 1966;45:391-412.
56. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404-409.
57. Mosli MH, Feagan BG, Sandborn WJ, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014;20:564-575.
58. Gore RM. Colonic contour changes in chronic ulcerative colitis: reappraisal of some old concepts. AJR Am J Roentgenol. 1992;158:59-61.
59. Mitomi H, Okayasu I, Bronner MP, et al. Comparative histologic assessment of proctocolectomy specimens from Japanese and American patients with ulcerative colitis with or without dysplasia. Int J Surg Pathol. 2005;13:259-265.
60. Lumb G, Protheroe RH. Ulcerative colitis; a pathologic study of 152 surgical specimens. Gastroenterology. 1958;34:381-407.
61. Dammeier J, Brauchle M, Falk W, et al. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int J Biochem Cell Biol. 1998;30:909-922.
62. Jones MK, Tomikawa M, Mohajer B, et al. Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci. 1999;4:D303-D309.
63. Swan NC, Geoghegan JG, O'Donoghue DP, et al. Fulminant colitis in inflammatory bowel disease: detailed pathologic and clinical analysis. Dis Colon Rectum. 1998;41:1511-1515.
64. Yantiss RK, Farraye FA, O'Brien MJ, et al. Prognostic significance of superficial fissuring ulceration in patients with severe "indeterminate" colitis. Am J Surg Pathol. 2006;30:165-170.
65. Yantiss RK, Odze RD. Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology. 2006;48:116-132.
66. North American Society for Pediatric Gastroenterology, Hepatology, Nutrition, Colitis Foundation of America. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44:653-674.
67. Odze RD. Pathology of indeterminate colitis. J Clin Gastroenterol. 2004;38:S36-S40.
68. Nasseri Y, Melmed G, Wang HL, et al. Rigorous histopathological assessment of the colectomy specimen in patients with inflammatory bowel disease unclassified does not predict outcome after ileal pouchanal anastomosis. Am J Gastroenterol. 2010;105:155-161.
69. Liu ZX, Deroche T, Remzi FH, et al. Transmural inflammation is not pathognomonic for Crohn's disease of the pouch. Surg Endosc. 2011;25: 3509-3517.
70. Torres J, Billioud V, Peyrin-Biroulet L, et al. Ulcerative colitis as a sole mucosal disease: another misunderstanding? Gut. 2012;61:633.
71. Kern F Jr, Almy TP, Abbot FK, et al. The motility of the distal colon in nonspecific ulcerative colitis. Gastroenterology. 1951;19:492-503.
72. Spriggs EA, Code CF, Bargen JA, et al. Motility of the pelvic colon and rectum of normal persons and patients with ulcerative colitis. Gastroenterology. 1951;19:480-491.
73. Aceves SS, Ackerman SJ. Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis. Immunol Allergy Clin North Am. 2009;29:197-211, xiii-xiv.
74. Rieder F, Biancani P, Harnett K, et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298: G571-G581.
75. Coulie B, Camilleri M, Bharucha AE, et al. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther. 2001;15: 653-663.
76. Bassotti G, Villanacci V, Mazzocchi A, et al. Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission. Eur J Gastroenterol Hepatol. 2006;18:507-510.
77. Snape WJ Jr, Matarazzo SA, Cohen S. Abnormal gastrocolonic response in patients with ulcerative colitis. Gut. 1980;21:392-396.
78. Loening-Baucke V, Metcalf AM, Shirazi S. Anorectal manometry in active and quiescent ulcerative colitis. Am J Gastroenterol. 1989;84: 892-897.
79. Loening-Baucke V, Metcalf AM, Shirazi S. Rectosigmoid motility in patients with quiescent and active ulcerative colitis. Am J Gastroenterol. 1989;84:34-39.
80. Reddy SN, Bazzocchi G, Chan S, et al. Colonic motility and transit in health and ulcerative colitis. Gastroenterology. 1991;101:1289-1297.
81. Koch TR, Carney JA, Go VL, et al. Spontaneous contractions and some electrophysiologic properties of circular muscle from normal sigmoid colon and ulcerative colitis. Gastroenterology. 1988;95:77-84.
82. Snape WJ Jr, Williams R, Hyman PE. Defect in colonic smooth muscle contraction in patients with ulcerative colitis. Am J Physiol. 1991;261: G987-G991.
83. Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Motil. 1998; 10:189-202.
84. Bernardini N, Segnani C, Ippolito C, et al. Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J Cell Mol Med. 2012;16:318-327.
85. Rao SS, Read NW, Brown C, et al. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology. 1987;93: 934-940.
86. Alp MH, Sage MR, Grant AK. The significance of widening of the presacral space at contrast radiography in inflammatory bowel disease. Aust N Z J Surg. 1978;48:175-177.
87. Chrispin AR, Fry IK. The presacral space shown by barium enema. Br J Radiol. 1963;36:319-322.
88. Wan M, Li C, Zhen G, et al. Injury-activated transforming growth factor beta controls mobilization of mesenchymal stem cells for tissue remodeling. Stem Cells. 2012;30:2498-2511.
89. Lepparanta O, Sens C, Salmenkivi K, et al. Regulation of TGF-beta storage and activation in the human idiopathic pulmonary fibrosis lung. Cell Tissue Res. 2012;348:491-503.
90. Schonherr E, Hausser HJ. Extracellular matrix and cytokines: a functional unit. Dev Immunol. 2000;7:89-101.
91. Franitza S, Hershkoviz R, Kam N, et al. TNF-alpha associated with extracellular matrix fibronectin provides a stop signal for chemotactically migrating T cells. J Immunol. 2000;165:2738-2747.
92. Vaday GG, Hershkoviz R, Rahat MA, et al. Fibronectin-bound TNFalpha stimulates monocyte matrix metalloproteinase-9 expression and regulates chemotaxis. J Leukoc Biol. 2000;68:737-747.
93. Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol. 2000;67:149-159.
94. Haseneen NA, Vaday GG, Zucker S, et al. Mechanical stretch induces MMP-2 release and activation in lung endothelium: role of EMMPRIN. Am J Physiol Lung Cell Mol Physiol. 2003;284: L541-L547.
95. Day AJ, de la Motte CA. Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol. 2005;26:637-643.
96. de la Motte CA, Hascall VC, Drazba J, et al. Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid:polycytidylic acid: inter-alpha-trypsin inhibitor is crucial to structure and function. Am J Pathol. 2003;163:121-133.
97. de la Motte C, Nigro J, Vasanji A, et al. Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol. 2009;174:2254-2264.
98. McDonald B, McAvoy EF, Lam F, et al. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. J Exp Med. 2008;205:915-927.
99. Brenmoehl J, Lang M, Hausmann M, et al. Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa. Int J Colorectal Dis. 2007;22:611-623.
100. Brenmoehl J, Falk W, Goke M, et al. Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). Int J Colorectal Dis. 2008;23:947-955.
101. Vaday GG, Franitza S, Schor H, et al. Combinatorial signals by inflammatory cytokines and chemokines mediate leukocyte interactions with extracellular matrix. J Leukoc Biol. 2001;69:885-892.
102. Brill A, Hershkoviz R, Vaday GG, et al. Augmentation of RANTESinduced extracellular signal-regulated kinase mediated signaling and T cell adhesion by elastase-treated fibronectin. J Immunol. 2001;166:7121-7127.
103. Johnson LA, Rodansky ES, Haak AJ, et al. Novel Rho/MRTF/SRF inhibitors Block matrix-stiffness and TGF-beta-induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis. 2014;20:154-165.
104. Johnson LA, Rodansky ES, Sauder KL, et al. Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts. Inflamm Bowel Dis. 2013;19:891-903.